Last reviewed · How we verify

NCT05808699

Camera Qualification Study

Active, enrolled Last updated 22 October 2024
What this trial tests

trial testing handheld fundus camera in Diabetic Retinopathy in 626 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
3 March 2023
Primary endpoint
30 November 2023
30 January 2025

Quick facts

Lead sponsorDigital Diagnostics, Inc.
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment626
Start date3 March 2023
Primary completion30 November 2023
Estimated completion30 January 2025
Sites9 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Digital Diagnostics, Inc.

Who can join

22 and older, any sex, with Diabetic Retinopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A multi-center study to evaluate the performance of an automated device for the detection of diabetic retinopathy with the use of an additional fundus camera with IDx-DR.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Mitigation of AI adoption bias through an improved autonomous AI system for diabetic retinal disease.
    Abràmoff MD, Lavin PT, Jakubowski JR, Blodi BA, et al · · 2024 · cited 6× · PMID 39702673 · DOI 10.1038/s41746-024-01389-x

Verify or expand the search:

Other recruiting trials for Diabetic Retinopathy

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05808699.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing